Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;27(12):1852-1856.
doi: 10.1002/lt.26273. Epub 2021 Sep 16.

Antibody Response to Severe Acute Respiratory Syndrome-Coronavirus-2 Messenger RNA Vaccines in Liver Transplant Recipients

Alexandra T Strauss  1 , Andrew M Hallett  2 , Brian J Boyarsky  2 , Michael T Ou  2 , William A Werbel  1 , Robin K Avery  1 , Aaron A R Tobian  3   4 , Allan B Massie  2 , James P A Hamilton  1 , Jacqueline M Garonzik-Wang  2 , Dorry L Segev  2   4
Affiliations

Antibody Response to Severe Acute Respiratory Syndrome-Coronavirus-2 Messenger RNA Vaccines in Liver Transplant Recipients

Alexandra T Strauss et al. Liver Transpl. 2021 Dec.
No abstract available

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
D1 and D2 semiquantitative SARS‐CoV‐2 anti‐spike antibody immunoassay results of LT recipients by assay type. The blood sampling protocol used 2 SARS‐CoV‐2 spike protein immunoassays (anti‐RBD and anti‐S1) and has been described elsewhere.( 1 ) Individual priming dose responders (D1+) are represented by blue lines connecting immunoassay results following D1 and D2. Individual booster responders and nonresponders (D1−) are represented by red points indicating immunoassay results following D2. Of 161 participants, 7 were tested using an anti‐RBD assay after D1 and an anti‐S1 assay after D2; these individuals are excluded from this figure. Antibody‐positive cutoffs (determined by the manufacturer and identified in the figure by horizontal red lines) were ≥0.80 U/mL for the anti‐RBD immunoassay (Roche Elecsys) and ≥1.1 arbitrary units for the anti‐S1 immunoassay (EUROIMMUN).
See this image and copyright information in PMC

Comment in

References

    1. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, Garonzik‐Wang JM. Immunogenicity of a single dose of SARS‐CoV‐2 messenger RNA vaccine in solid organ transplant recipients. JAMA 2021;325:1784‐1786. - PMC - PubMed
    1. Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA‐based Covid‐19 vaccine candidates. N Engl J Med 2020;17:2439‐2450. - PMC - PubMed
    1. Boyarsky BJ, Ou MT, Greenberg RS, Teles AT, Werbel WA, Avery RK, et al. Safety of the first dose of SARS‐CoV‐2 vaccination in solid organ transplant recipients. Transplantation 2021;105:e56‐e57. - PMC - PubMed
    1. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al. Antibody response to 2‐dose SARS‐CoV‐2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021;325:2204. - PMC - PubMed
    1. Rabinowich L, Grupper A, Baruch R, Ben‐Yehoyada M, Halperin T, Turner D, et al. Low immunogenicity to SARS‐CoV‐2 vaccination among liver transplant recipients. J Hepatol 2021;75:435‐438. - PMC - PubMed

Publication types